You are here

Generic Version of Alesse Receives FDA Approval

CORONA, Calif., Nov. 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI - News), a leading specialty pharmaceutical company, announced today that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application for levonorgestrel and ethinyl estradiol tablets USP, 0.1mg / 0.02mg, a generic version of Wyeth's Alesse®, which is indicated for the prevention of pregnancy.

The Company intends to initiate shipments of the product immediately under the trade name LUTERA(TM). For the 12-months ending September 2004, the levonorgestrel and ethinyl estradiol tablets USP, 0.1mg / 0.02mg market had total U.S. sales of approximately $163 million, according to IMS Health data.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut